Research graph
References from Prominin-1 (CD133) is essential for the determination of the phenotype of Philadelphia chromosome-positive leukemia. Local targets link to admitted publications; unresolved targets remain external evidence.
Chronic Myeloid Leukemia: Modern therapies, current challenges and future directions
10.1016/j.blre.2021.100825 · 2021 · External reference
The biology of chronic myeloid leukemia
10.1056/nejm199907153410306 · 1999 · External reference
PF-114, a potent and selective inhibitor of native and mutated BCR/ABL is active against Philadelphia chromosome-positive (Ph+) leukemias harboring the T315I mutation
10.1038/leu.2014.326 · 2015 · External reference
Reversibility of acute B-cell leukaemia induced by BCR-ABL1
10.1038/71691 · 2000 · External reference
The P190, P210, and P230 forms of the BCR/ABL oncogene induce a similar chronic myeloid leukemia-like syndrome in mice but have different lymphoid leukemogenic activity
10.1084/jem.189.9.1399 · 1999 · External reference
Targeting BCR-ABL1-positive leukaemias: a review article
10.1017/pcm.2023.9 · 2023 · External reference
The allosteric inhibitor ABL001 enables dual targeting of BCR-ABL1
10.1038/nature21702 · 2017 · External reference
Sequential ABL kinase inhibitor therapy selects for compound drug-resistant BCR-ABL mutations with altered oncogenic potency
10.1172/jci30890 · 2007 · External reference
Seeking the causes and solutions to imatinib-resistance in chronic myeloid leukemia
10.1038/leu.2010.238 · 2011 · External reference
Philadelphia chromosome-positive cells are equally distributed in AC133+ and AC133- fractions of CD34+ peripheral blood progenitor cells from patients with CML
10.1038/sj.leu.2401516 · 1999 · External reference
Characterization of prominin-2, a new member of the prominin family of pentaspan membrane glycoproteins
10.1074/jbc.m210640200 · 2003 · External reference
Nomenclature of prominin-1 (CD133) splice variants - an update
10.1111/j.1399-0039.2007.00825.x · 2007 · External reference
AC133, a novel marker for human hematopoietic stem and progenitor cells
10.1182/blood.v90.12.5002 · 1997 · External reference
A novel five-transmembrane hematopoietic stem cell antigen: isolation, characterization, and molecular cloning
10.1182/blood.v90.12.5013 · 1997 · External reference
Emerging roles of prominin-1 (CD133) in the dynamics of plasma membrane architecture and cell signaling pathways in health and disease
10.1186/s11658-024-00554-0 · 2024 · External reference
Isolation and characterization of human CD34(-)Lin(-) and CD34(+)Lin(-) hematopoietic stem cells using cell surface markers AC133 and CD7
10.1182/blood.v95.9.2813.009k20_2813_2820 · 2000 · External reference
Comparative analysis of proliferative potential and clonogenicity of MACS-immunomagnetic isolated CD34+ and CD133+ blood stem cells derived from a single donor
10.1111/j.1365-2184.2006.00386.x · 2006 · External reference
Multipotent hematopoietic progenitors divide asymmetrically to create progenitors of the lymphomyeloid and erythromyeloid lineages
10.1016/j.stemcr.2014.09.016 · 2015 · External reference
CD133 is a modifier of hematopoietic progenitor frequencies but is dispensable for the maintenance of mouse hematopoietic stem cells
10.1073/pnas.1215438110 · 2013 · External reference
The human AC133 hematopoietic stem cell antigen is also expressed in epithelial cells and targeted to plasma membrane protrusions
10.1074/jbc.275.8.5512 · 2000 · External reference
Loss of the cholesterol-binding protein prominin-1/CD133 causes disk dysmorphogenesis and photoreceptor degeneration
10.1523/jneurosci.2034-08.2009 · 2009 · External reference
Prominin, a novel microvilli-specific polytopic membrane protein of the apical surface of epithelial cells, is targeted to plasmalemmal protrusions of non-epithelial cells
10.1073/pnas.94.23.12425 · 1997 · External reference
Retention of prominin in microvilli reveals distinct cholesterol-based lipid micro-domains in the apical plasma membrane
10.1038/35023524 · 2000 · External reference
Haematopoietic stem cell differentiation promotes the release of prominin-1/CD133-containing membrane vesicles–a role of the endocytic-exocytic pathway
10.1002/emmm.201100147 · 2011 · External reference
Prominin-1 controls stem cell activation by orchestrating ciliary dynamics
10.15252/embj.201899845 · 2019 · External reference
Prominin-1 (CD133) modulates the architecture and dynamics of microvilli
10.1111/tra.12618 · 2019 · External reference
Release of extracellular membrane particles carrying the stem cell marker prominin-1 (CD133) from neural progenitors and other epithelial cells
10.1242/jcs.02439 · 2005 · External reference
The stem cell marker CD133 (prominin-1) is phosphorylated on cytoplasmic tyrosine-828 and tyrosine-852 by Src and Fyn tyrosine kinases
10.1021/bi900159d · 2009 · External reference
Activation of PI3K/Akt pathway by CD133-p85 interaction promotes tumorigenic capacity of glioma stem cells
10.1073/pnas.1217002110 · 2013 · External reference
CD133 as a biomarker for putative cancer stem cells in solid tumours: limitations, problems and challenges
2013 · External reference
Targeting CD133 antigen in cancer
10.1517/14728220903005616 · 2009 · External reference
AC133 antigen expression is not restricted to acute myeloid leukemia blasts but is also found on acute lymphoid leukemia blasts and on a subset of CD34+ B-cell precursors
10.1182/blood.v94.2.832 · 1999 · External reference
Expression of AC133 and CD117 on candidate normal stem cell populations in childhood B-cell precursor acute lymphoblastic leukaemia
10.1046/j.1365-2141.1999.01746.x · 1999 · External reference
p185(BCR/ABL) has a lower sensitivity than p210(BCR/ABL) to the allosteric inhibitor GNF-2 in Philadelphia chromosome-positive acute lymphatic leukemia
10.3324/haematol.2011.047191 · 2012 · External reference
BCR-ABL mediates arsenic trioxide-induced apoptosis independently of its aberrant kinase activity
2000 · External reference
Targeting of the N-terminal coiled coil oligomerization interface of BCR interferes with the transformation potential of BCR-ABL and increases sensitivity to STI571
10.1182/blood-2003-03-0811 · 2003 · External reference
on behalf of the GMALL study group. Randomized comparison of prophylactic and minimal residual disease-triggered imatinib after allogeneic stem cell transplantation for BCR–ABL1-positive acute lymphoblastic leukemia
10.1038/leu.2012.352 · 2013 · External reference
Targeting of the N-terminal coiled coil oligomerization interface by a helix-2 peptide inhibits unmutated and imatinib-resistant BCR/ABL
10.1002/ijc.23467 · 2008 · External reference
The stem cell marker CD133 (Prominin-1) is expressed in various human glandular epithelia
10.1369/jhc.2008.951897 · 2008 · External reference
The t(6;9) associated DEK/CAN fusion protein targets a population of long-term repopulating hematopoietic stem cells for leukemogenic transformation
10.1038/leu.2010.180 · 2010 · External reference
Persistence of malignant hematopoietic progenitors in chronic myelogenous leukemia patients in complete cytogenetic remission following imatinib mesylate treatment
10.1182/blood-2002-09-2780 · 2003 · External reference
Differential effects of selective inhibitors targeting the PI3K/AKT/mTOR pathway in acute lymphoblastic leukemia
10.1371/journal.pone.0080070 · 2013 · External reference
Long-term culture of primary human lymphoblastic leukemia cells in the absence of serum or hematopoietic growth factors
10.1016/j.exphem.2008.11.002 · 2009 · External reference
5-Lipoxygenase is a candidate target for therapeutic management of stem cell-like cells in acute myeloid leukemia
10.1158/0008-5472.can-13-3012 · 2014 · External reference
CD133 in Breast Cancer Cells: More than a Stem Cell Marker
10.1155/2019/7512632 · 2019 · External reference
Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia
10.1056/nejm200104053441401 · 2001 · External reference
A phase 2 study of imatinib in patients with relapsed or refractory Philadelphia chromosome-positive acute lymphoid leukemias
10.1182/blood-2001-12-0181 · 2002 · External reference
Despite inhibition of hematopoietic progenitor cell growth in vitro, the tyrosine kinase inhibitor imatinib does not impair engraftment of human CD133+ cells into NOD/SCIDbeta2mNull mice
10.1634/stemcells.2005-0290 · 2006 · External reference
Kinase-targeted cancer therapies: progress, challenges and future directions
10.1186/s12943-018-0804-2 · 2018 · External reference
Allosteric kinase inhibition in hematological malignancies: from asciminib to emerging regulatory sites
10.1016/j.bcp.2026.118436 · 2026 · External reference
A general strategy for creating "inactive-conformation" abl inhibitors
10.1016/j.chembiol.2006.05.015 · 2006 · External reference
Crystal structures of the kinase domain of c-Abl in complex with the small molecule inhibitors and imatinib (STI-571)
2002 · External reference
A type-II kinase inhibitor capable of inhibiting the T315I "gatekeeper" mutant of Bcr-Abl
10.1021/jm901808w · 2010 · External reference
Advances in the structural biology, design and clinical development of Bcr-Abl kinase inhibitors for the treatment of chronic myeloid leukaemia
10.1016/j.bbapap.2005.07.040 · 2005 · External reference
